Juvenile Idiopathic Arthritis (JIA)

  1. Overview
  2. Subtypes (ILAR Classification)
  3. Uveitis and Eye Disease
  4. Diagnosis
  5. Treatment — Step-Up Approach
  6. Biologic Therapies
  7. Macrophage Activation Syndrome
  8. Long-Term Outcomes and Growth
  9. Key Research Papers
  10. Connections

Overview

Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease of childhood, and one of the most significant causes of disability and eye disease in children in developed countries. The term "idiopathic" means no identifiable underlying cause has been established — it is a diagnosis of exclusion. By definition, JIA encompasses all forms of arthritis beginning before age 16, present for more than 6 weeks, and with no identifiable cause.

The incidence ranges widely across populations, from approximately 8 to 150 per 100,000 children per year, reflecting genuine geographic variation as well as differences in case ascertainment. Prevalence is estimated at roughly 1 per 1,000 children, making JIA comparable in burden to childhood type 1 diabetes. Most subtypes show female predominance, though enthesitis-related arthritis disproportionately affects older boys.

The fundamental pathology is chronic synovitis — persistent inflammation of the synovial membrane lining the joints. If inadequately controlled, this leads to cartilage erosion, bone damage, joint deformity, and growth disturbances. JIA can also affect the eyes (uveitis), skin, and internal organs depending on subtype. The disease course is highly variable: some children achieve sustained remission, others carry active disease into adulthood.

JIA replaced older terms such as "juvenile rheumatoid arthritis" (JRA, used in North America) and "juvenile chronic arthritis" (JCA, used in Europe). The current International League of Associations for Rheumatology (ILAR) classification defines seven subtypes based on the number of joints involved, the presence of specific autoantibodies, and associated systemic features.

Back to Table of Contents

Subtypes (ILAR Classification)

The 2001 ILAR classification divides JIA into seven subtypes, each with distinct clinical features, immunogenetics, prognosis, and treatment implications.

1. Oligoarticular JIA (approximately 50% of cases)

The most common subtype. Involves four or fewer joints during the first six months of disease. Typically affects large joints — knees, ankles, wrists — asymmetrically. Antinuclear antibody (ANA) is positive in 60–80% of cases. The risk of chronic anterior uveitis is highest in this subtype, particularly in ANA-positive young girls. Extended oligoarticular JIA is diagnosed when the disease involves more than four joints after the first six months; it carries a worse prognosis.

2. Polyarticular RF-negative JIA (approximately 20% of cases)

Involves five or more joints from onset, with rheumatoid factor (RF) negative. Can affect both large and small joints, including the temporomandibular joint and cervical spine. ANA may be positive. Carries moderate risk of uveitis. Generally responds well to methotrexate.

3. Polyarticular RF-positive JIA (5–10% of cases)

Involves five or more joints with persistently positive RF (on two occasions at least three months apart). Anti-cyclic citrullinated peptide (anti-CCP) antibodies are often present. HLA-DR4 association is strong. This subtype behaves most like adult rheumatoid arthritis — it is erosive and destructive — and rarely remits spontaneously. It is uncommon before age 8.

4. Systemic JIA / Still's Disease (10–15% of cases)

Distinguished by prominent systemic features alongside arthritis: quotidian (once or twice daily spiking) fever of at least two weeks' duration, a characteristic salmon-colored evanescent rash that appears during fever spikes, and one or more of hepatosplenomegaly, generalized lymphadenopathy, or serositis (pericarditis, pleuritis). Arthritis may follow the systemic features by weeks to months. Driven by the innate immune system via IL-1 and IL-6 (rather than adaptive T-cell responses dominant in other subtypes), which explains the efficacy of IL-1 and IL-6 antagonists. Carries significant risk of macrophage activation syndrome (MAS).

5. Psoriatic JIA

Diagnosed when arthritis is accompanied by psoriasis, OR when arthritis is accompanied by two of the following minor criteria: dactylitis (sausage digit), nail pitting or onycholysis, or a first-degree family history of psoriasis. The arthritis can precede psoriasis by years. Dactylitis is a distinctive feature. Uveitis risk is present.

6. Enthesitis-Related Arthritis (ERA)

Characterized by arthritis and/or enthesitis (inflammation at tendon/ligament insertion sites, especially the Achilles tendon and plantar fascia). HLA-B27 is present in approximately 80% of cases. Predominantly affects older boys (>8 years). Sacroiliac joint involvement distinguishes ERA from other JIA subtypes. Associated with inflammatory bowel disease (IBD). ERA is considered a precursor to ankylosing spondylitis in many patients.

7. Undifferentiated JIA

Arthritis that fulfills criteria for more than one JIA category, or fulfills no category criteria, falls here. It represents a heterogeneous group.

Back to Table of Contents

Uveitis and Eye Disease

JIA-associated uveitis is one of the most serious complications of the disease and a leading cause of preventable blindness in children. It typically takes the form of chronic anterior uveitis — inflammation of the anterior chamber of the eye.

The insidious danger of JIA uveitis is that it is characteristically asymptomatic. Unlike acute uveitis in adults (which causes a painful red eye), JIA-associated uveitis causes no pain, no redness, and no visual symptoms until irreversible damage has occurred. Band keratopathy (calcium deposits across the cornea), posterior synechiae, cataract, glaucoma, and ultimately blindness can all result from untreated or undertreated inflammation.

Risk factors for uveitis include: oligoarticular subtype, ANA positivity, young age at disease onset, and female sex. Children with ANA-positive oligoarticular JIA diagnosed before age 7 are at highest risk.

Screening Intervals

Because of the silent nature of this complication, mandatory ophthalmologic screening by slit-lamp examination is essential. Recommended intervals vary by risk category:

Screening must continue for years after joint disease remits, because uveitis can persist or even develop after the arthritis has quieted.

Treatment of JIA Uveitis

Topical corticosteroid eye drops and mydriatics (to prevent posterior synechiae) are first-line. Systemic methotrexate is added for steroid-dependent or recurrent uveitis. Adalimumab (a TNF inhibitor) is now the biologic of choice for refractory JIA uveitis — it has the strongest evidence and is licensed for this indication. Systemic JIA rarely develops uveitis.

Back to Table of Contents

Diagnosis

JIA is a clinical diagnosis. There is no single diagnostic test. The diagnosis requires arthritis (joint swelling, OR pain and limited range of motion) lasting at least 6 weeks, onset before age 16, and exclusion of other causes.

Key Differential Diagnoses to Exclude

Laboratory Investigations

Imaging

Back to Table of Contents

Treatment — Step-Up Approach

JIA treatment follows a step-up approach: start with the least toxic effective therapy and escalate based on disease activity, subtype, and response. The goal is to achieve sustained clinical remission — defined as no active arthritis, no fever, no rash, no serositis, no splenomegaly, normal ESR/CRP, and physician global assessment of no disease activity for a defined period.

NSAIDs

Naproxen (10–20 mg/kg/day in two divided doses) and ibuprofen are commonly used for analgesia and anti-inflammatory effect. NSAIDs control symptoms but do not prevent joint damage or uveitis. They are appropriate as sole therapy only for mild oligoarticular disease in the early weeks of diagnosis while the full picture is being established. Naproxen-induced pseudoporphyria (skin fragility in sun-exposed areas) is a notable pediatric adverse effect.

Intraarticular Corticosteroids

Intraarticular injection of triamcinolone acetonide hexacetonide is highly effective for oligoarticular JIA. A single injection can induce remission for months to years in some patients. This approach minimizes systemic steroid exposure. Repeated injections are acceptable. Ultrasound guidance improves accuracy.

Systemic Corticosteroids

Used as a short-term bridge while awaiting DMARD effect, or in systemic JIA for acute control of fever and serositis. Long-term systemic steroids are avoided due to severe side effects in growing children: growth suppression, osteoporosis, adrenal suppression, Cushingoid features, and increased infection risk.

Disease-Modifying Antirheumatic Drugs (DMARDs)

Methotrexate (MTX) at 10–15 mg/m² once weekly (oral or subcutaneous) is the anchor DMARD for polyarticular JIA. It is also used for oligoarticular extended disease and uveitis. Folic acid supplementation (1 mg/day) reduces mucosal and hematologic side effects. Liver toxicity and pulmonary toxicity are rare at pediatric doses but require monitoring (LFTs, CBC). Takes 3–6 months for full effect.

Sulfasalazine is used preferentially for ERA subtype (evidence for sacroiliac involvement; also used in IBD-associated arthritis).

Hydroxychloroquine is occasionally used for mild polyarticular disease, though evidence in JIA is limited.

Back to Table of Contents

Biologic Therapies

Biologic agents — targeted therapies against specific cytokines or immune pathways — have transformed JIA outcomes. They are indicated when the disease is inadequately controlled by conventional DMARDs, when there is severe or erosive polyarticular disease, or when systemic features require IL-1 or IL-6 blockade.

TNF Inhibitors

T-Cell Co-stimulation Blockade

Abatacept (CTLA-4-Ig fusion protein) blocks the CD28–CD80/86 co-stimulatory signal required for T-cell activation. FDA-approved for polyarticular JIA ≥6 years. Intravenous monthly infusion or weekly subcutaneous injection. Evidence from the NEJM trial by Ruperto et al. demonstrated efficacy in MTX-inadequate responders.

IL-6 Receptor Blockade

Tocilizumab: blocks the IL-6 receptor; FDA-approved for systemic JIA ≥2 years and polyarticular JIA ≥2 years. Particularly effective for the systemic features of sJIA (fever, rash, elevated acute-phase reactants). Intravenous infusion or subcutaneous injection.

IL-1 Blockade

Canakinumab (anti-IL-1β monoclonal antibody): FDA-approved for systemic JIA ≥2 years; subcutaneous injection every 4 weeks. Highly effective for fever and systemic features. Anakinra (IL-1 receptor antagonist, daily subcutaneous) is used off-label for systemic JIA and acute MAS management.

JAK Inhibitors

Tofacitinib (JAK1/3 inhibitor) has been studied in polyarticular JIA and has received approval in some jurisdictions. Oral administration is advantageous for children who struggle with injections.

Safety Considerations for All Biologics

Back to Table of Contents

Macrophage Activation Syndrome (MAS)

Macrophage Activation Syndrome (MAS) is a life-threatening complication occurring most commonly in systemic JIA, though it can be triggered in other JIA subtypes and in other rheumatic diseases. It represents a form of secondary hemophagocytic lymphohistiocytosis (HLH) — an uncontrolled hyperactivation of macrophages and cytotoxic T lymphocytes producing a massive cytokine storm.

Clinical Features

The cardinal features of MAS include:

The Ferritin Signal

Ferritin is the most sensitive laboratory marker. A ferritin level above 500 ng/mL in a child with sJIA fever should prompt urgent reassessment. Above 10,000 ng/mL, MAS becomes highly probable. The 2016 Ravelli et al. classification criteria for MAS in sJIA require ferritin >684 ng/mL plus two or more of: platelet ≤181×10⁹/L; AST >48 U/L; triglycerides >156 mg/dL; fibrinogen ≤360 mg/dL.

Triggers

Common triggers include intercurrent viral infections (especially EBV, CMV), changes in medications, and disease flares. MAS can occur at initial presentation of sJIA before any treatment has been started.

Treatment

MAS requires ICU-level care. High-dose intravenous methylprednisolone is first-line. Cyclosporine A is added for steroid-refractory cases. Anakinra (IL-1 receptor antagonist) at high doses has shown efficacy in sJIA-MAS and is used increasingly. Etoposide is employed in severe or refractory cases, borrowed from primary HLH protocols. Without prompt aggressive treatment, MAS carries significant mortality.

Back to Table of Contents

Long-Term Outcomes and Growth

JIA outcomes have improved dramatically in the biologic era, but a substantial minority of patients experience persistent or relapsing disease into adulthood.

Remission Rates

Approximately 50% of JIA patients achieve sustained clinical remission, though rates vary markedly by subtype. Oligoarticular JIA has the best prognosis — many patients achieve remission within years, though uveitis may persist. Polyarticular RF-negative JIA has intermediate outcomes. Polyarticular RF-positive JIA has the worst prognosis among subtypes, with the lowest remission rates and the most structural joint damage. Systemic JIA has a bimodal course: a monocyclic form (30%) that remits completely, a polycyclic form (30%) with flares, and a chronic persistent form (30–40%) with ongoing joint destruction and MAS risk.

Growth and Skeletal Development

Active inflammation and corticosteroid use both impair linear growth. Local joint inflammation can cause accelerated bone maturation in the affected limb early in disease, followed by growth plate damage and limb length discrepancy. Micrognathia (small jaw) results from temporomandibular joint involvement. Cervical spine fusion can occur in polyarticular disease. Generalized osteoporosis from inflammation and steroid use increases fracture risk. Nutritional support and vitamin D supplementation are important adjuncts.

Quality of Life, School, and Work

JIA impairs quality of life across physical, emotional, and social domains. Fatigue is common and underappreciated — it affects school attendance and social participation. Pain, morning stiffness, and medication side effects add to the burden. Physical therapy and occupational therapy are crucial throughout the disease course — not just for acute flares but for maintaining strength, range of motion, and function during remission.

Transition to Adult Care

Transition from pediatric rheumatology to adult rheumatology is a vulnerable period. Approximately one-third of JIA patients still have active disease at age 18. Structured transition programs improve medication adherence and follow-up rates. Adult rheumatologists need to be aware that JIA-onset RA (polyarticular RF+) may have different disease history and medication exposure compared to adult-onset RA.

Psychological Impact

Depression and anxiety are more common in children with JIA than in healthy peers. Peer relationships, sports participation, and self-image are all affected. Psychological support, peer support groups, and school accommodation plans are important components of comprehensive care.

Back to Table of Contents

Key Research Papers

  1. Petty RE et al., 2004 — International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001 — PMID: 11759859
  2. Ravelli A, Martini A, 2007 — Juvenile idiopathic arthritis (Lancet comprehensive review) — PMID: 16799003
  3. Cassidy J et al., 2005 — Juvenile idiopathic arthritis classification update — PMID: 15592580
  4. Lovell DJ et al., 2000 — Etanercept in children with polyarticular juvenile rheumatoid arthritis (New England Journal of Medicine pivotal trial) — PMID: 10880518
  5. Ruperto N et al., 2008 — Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial (New England Journal of Medicine) — PMID: 18077811
  6. Ruperto N et al., 2011 — Two randomized trials of tocilizumab in systemic juvenile idiopathic arthritis (New England Journal of Medicine) — PMID: 21084087
  7. Cassidy JT et al., 2006 — Ophthalmologic examinations in children with juvenile rheumatoid arthritis (Pediatrics) — PMID: 21562234
  8. Ringold S et al., 2019 — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis — PMID: 30951259
  9. De Benedetti F et al., 2012 — Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis — PMID: 23163773
  10. Ravelli A et al., 2016 — 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis — PMID: 27111829
  11. Wallace CA et al., 2004 — Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis — PMID: 14730600
  12. Gutierrez-Suarez R et al., 2018 — Adalimumab for the treatment of JIA-associated uveitis — PMID: 29478671

PubMed Topic Searches

  1. Juvenile idiopathic arthritis treatment biologics — PubMed
  2. JIA uveitis screening adalimumab — PubMed
  3. Systemic JIA macrophage activation syndrome — PubMed
  4. Juvenile idiopathic arthritis methotrexate outcomes — PubMed

Back to Table of Contents

Connections

Back to Table of Contents